Page 3 - David Marek News Today

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

03.01.2022 - BASEL, Switzerland, Jan. 03, 2022 (GLOBE NEWSWIRE) - Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, Chief Executive Officer of Myovant Sciences, Inc., will ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

ThreatMark, provider of the most advanced online fraud prevention solution in the market, has completed a new $3M funding round led by Springtide Ventures,...

Ceny v České republice stále rychle rostou. Inflace v srpnu stoupla o 4,2 %, což je nejvíce od listopadu roku 2008. Podle ekonomů se však nejedná o žádný výkyv a počítají i v následujících měsících s dalším zdražováním.

Tragickou zprávu přinesl Kuba Ryba z kapely Rybičky 48, s kterou Štrup fungoval v minulosti jako kytarista. „Před chvílí jsem se dozvěděl, že odešel Honza Štrup… Nebudu se rozepisovat o tom, jak jsme se poznali, co jsme spolu zažili a co se stalo, že jsme se posledních X let nebavili…,“ uvedl na facebooku Ryba. „Měl to v hlavě složité, stáhnul se do sebe a moc s nikým v poslední době nekomunikoval,“ svěřil Blesku jeden z kolegů kytaristy. Podle něj spác...

In the Phase 3 LIBERTY 1 and LIBERTY 2 studies, MYFEMBREE demonstrated 72.1% and 71.2% response rates in menstrual blood loss (MBL) at Week 24, with MBL...

Pfizer And Myovant Get FDA Nod For Myfembree NEW YORK CITY (dpa-AFX) - Pfizer Inc. and Myovant Sciences announced that the U.S. Food and Drug Administration has approved Myfembree, the first once-daily treatment for heavy menstrual bleeding associated with uterine fibroids. Under the collaboration terms, Myovant and Pfizer will jointly commercialize Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) in the U.S. The drug is expected to be available in June 2021. Myfemb...

Search jobs 27-May-2021 Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated with Uterine Fibroids In the Phase 3 LIBERTY 1 and LIBERTY 2 studies, MYFEMBREE demonstrated 72.1% and 71.2% response rates in menstrual blood loss (MBL) at Week 24, with MBL reductions of 82.0% and 84.3% from baseline Myovant and Pfizer will jointly commercialize MYFEMBREE, with product avai...

/PRNewswire/ -- Sumitovant Biopharma, Inc. today announced that its portfolio of four wholly owned subsidiary companies (Urovant, Enzyvant, Altavant and...